Gameto
UruguayLogistics
Gameto is a reproductive health biotechnology company developing treatments to improve fertility care. Its lead product, Fertilo, is a stem cell-based therapy designed to mature eggs outside the body to reduce the number of hormone injections and shorten IVF cycles. The company also has programs including Ameno and Deovo in its pipeline. Gameto targets fertility clinics and patients, with clinical trials recruiting in the U.S. and partnerships with global fertility clinics. It has raised $117 million in venture funding, secured a $10 million ARPA-H award, and announced a $44 million Series C round.
2 funding rounds tracked. Follow the profile to review the shared record and its sources.
Open profile
Open profile
Key people
- Dina Radenkovic Turner Co-founder & CEO
- Martín Varsavsky Co-founder